Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SBTX · Entity 883 | Director | December 08, 2020 | December 09, 2020 |
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | Director | May 22, 2019 | May 23, 2019 |
| PMV Pharmaceuticals, Inc.PMVP · Entity 7062 | Director | October 06, 2021 | October 08, 2021 |
| Revolution Medicines, Inc.RVMD · Entity 606 | Director | December 05, 2024 | December 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date December 08, 2020 · Filed December 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Nextech VI Oncology SCSp | 1,910,029 |
Last balance in matching sequence
After 2020-12-08 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2020-12-08 · Purchase · Acquired 238,096 · Balance 238,096 F1: The shares were purchased in the Issuer's initial public offering. F2: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Row 2 · 2020-12-08 · Conversion · Acquired 1,246,870 · Balance 1,484,966 F3: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Row 3 · 2020-12-08 · Conversion · Acquired 425,063 · Balance 1,910,029 F3: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Nextech VI Oncology SCSp | 0 |
Reported balance
After 2020-12-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-08 · Conversion · Disposed 4,629,630 · Balance 0 F3: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Nextech VI Oncology SCSp | 0 |
Reported balance
After 2020-12-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-08 · Conversion · Disposed 1,578,259 · Balance 0 F3: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were purchased in the Issuer's initial public offering.
F2: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.
IDEAYA Biosciences, Inc.
Report date May 22, 2019 · Filed May 23, 2019
This filing explicitly reported no securities owned.
PMV Pharmaceuticals, Inc.
Report date October 06, 2021 · Filed October 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,101,283 |
Reported balance
After 2021-10-06 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-10-06 · Sale · Disposed 800 · Balance 1,101,283 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.03 to $30.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were sold pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.03 to $30.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.
Revolution Medicines, Inc.
Report date December 05, 2024 · Filed December 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Nextech Crossover I SCSP | 2,096,612 |
Reported balance
After 2024-12-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-12-05 · Purchase · Acquired 543,478 · Balance 2,096,612 F1: Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The Reporting Person is a managing member of Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nextech VIII SCSP | 760,869 |
Reported balance
After 2024-12-05 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-12-05 · Purchase · Acquired 760,869 · Balance 760,869 F2: Nextech Invest AG is the investment advisor of Nextech VIII SCSP ("Nextech VIII"). The Reporting Person is a managing member of Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VIII. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nextech V Oncology S.C.S., SICAV-SIF | 3,590,313 |
Reported balance
Holding disclosure · report date 2024-12-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,590,313 F3: Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The Reporting Person is a managing member of Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nextech VI Oncology SCSp | 1,153,293 |
Reported balance
Holding disclosure · report date 2024-12-05 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,153,293 F4: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The Reporting Person is a managing member of Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The Reporting Person is a managing member of Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F2: Nextech Invest AG is the investment advisor of Nextech VIII SCSP ("Nextech VIII"). The Reporting Person is a managing member of Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VIII. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3: Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The Reporting Person is a managing member of Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F4: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The Reporting Person is a managing member of Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2021 Filed May 27, 2021 23:41 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 8,518 | $35.91 | $305,881.38 |
DisclosureSEC source: 0001209191-21-036352 · doc4.xml · nonDerivative · entry 1 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,051,116 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.66 to 36.32 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 24, 2021 Filed May 24, 2021 23:59 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 22,095 | $36.03 | $796,082.85 |
DisclosureSEC source: 0001209191-21-035544 · doc4.xml · nonDerivative · entry 3 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,059,634 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.61 to $36.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 21, 2021 Filed May 24, 2021 23:59 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 19,774 | $35.84 | $708,700.16 |
DisclosureSEC source: 0001209191-21-035544 · doc4.xml · nonDerivative · entry 2 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,081,729 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.60 to $36.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 20, 2021 Filed May 24, 2021 23:59 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 2,911 | $35.65 | $103,777.15 |
DisclosureSEC source: 0001209191-21-035544 · doc4.xml · nonDerivative · entry 1 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,101,503 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.61 to 35.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 10, 2021 Filed May 12, 2021 23:46 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 1,787 | $35.67 | $63,742.29 |
DisclosureSEC source: 0001209191-21-032222 · doc4.xml · nonDerivative · entry 1 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,104,414 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.60 to 35.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 05, 2021 Filed May 7, 2021 22:56 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 600 | $35.64 | $21,384.00 |
DisclosureSEC source: 0001209191-21-031052 · doc4.xml · nonDerivative · entry 1 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,106,201 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.60 to 35.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 01:07 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 100 | $33.11 | $3,311.00 |
DisclosureSEC source: 0001209191-21-026547 · doc4.xml · nonDerivative · entry 5 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,106,801 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 01:07 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 900 | $32.00 | $28,800.00 |
DisclosureSEC source: 0001209191-21-026547 · doc4.xml · nonDerivative · entry 4 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,106,901 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.92 to $32.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 01:07 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 2,903 | $31.17 | $90,486.51 |
DisclosureSEC source: 0001209191-21-026547 · doc4.xml · nonDerivative · entry 3 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,107,801 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.86 to $31.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 09, 2021 Filed Apr 14, 2021 01:07 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 19,858 | $34.89 | $692,845.62 |
DisclosureSEC source: 0001209191-21-026547 · doc4.xml · nonDerivative · entry 2 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,110,704 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.34 to $35.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 09, 2021 Filed Apr 14, 2021 01:07 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 5,905 | $33.75 | $199,293.75 |
DisclosureSEC source: 0001209191-21-026547 · doc4.xml · nonDerivative · entry 1 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,130,562 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.27 to 34.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 08, 2021 Filed Apr 8, 2021 23:24 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 20,701 | $34.23 | $708,595.23 |
DisclosureSEC source: 0001209191-21-026157 · doc4.xml · nonDerivative · entry 6 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,136,467 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.02 to $34.51 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 08, 2021 Filed Apr 8, 2021 23:24 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 12,621 | $33.82 | $426,842.22 |
DisclosureSEC source: 0001209191-21-026157 · doc4.xml · nonDerivative · entry 5 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,157,168 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.02 to $34.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 23:24 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 100 | $34.50 | $3,450.00 |
DisclosureSEC source: 0001209191-21-026157 · doc4.xml · nonDerivative · entry 4 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,169,789 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 23:24 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 24,357 | $33.88 | $825,215.16 |
DisclosureSEC source: 0001209191-21-026157 · doc4.xml · nonDerivative · entry 3 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,169,889 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.26 to $34.23 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 23:24 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 67,086 | $34.67 | $2,325,871.62 |
DisclosureSEC source: 0001209191-21-026157 · doc4.xml · nonDerivative · entry 2 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,194,246 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.13 to $35.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 23:24 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 11,571 | $33.85 | $391,678.35 |
DisclosureSEC source: 0001209191-21-026157 · doc4.xml · nonDerivative · entry 1 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,261,332 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.11 to 34.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 23:04 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 29,203 | $34.03 | $993,778.09 |
DisclosureSEC source: 0001209191-21-025463 · doc4.xml · nonDerivative · entry 3 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,272,903 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.83 to $34.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 23:04 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 18,990 | $33.46 | $635,405.40 |
DisclosureSEC source: 0001209191-21-025463 · doc4.xml · nonDerivative · entry 2 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,302,106 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.83 to $33.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 23:04 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 12,435 | $32.94 | $409,608.90 |
DisclosureSEC source: 0001209191-21-025463 · doc4.xml · nonDerivative · entry 1 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,321,096 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.42 to $33.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 01:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 13,645 | $32.93 | $449,329.85 |
DisclosureSEC source: 0001209191-21-023909 · doc4.xml · nonDerivative · entry 7 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,333,531 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.79 to $33.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 01:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 18,381 | $32.33 | $594,257.73 |
DisclosureSEC source: 0001209191-21-023909 · doc4.xml · nonDerivative · entry 6 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,347,176 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.79 to $32.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 01:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 1,600 | $31.19 | $49,904.00 |
DisclosureSEC source: 0001209191-21-023909 · doc4.xml · nonDerivative · entry 5 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,365,557 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.74 to $31.58 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 01:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 3,276 | $31.19 | $102,178.44 |
DisclosureSEC source: 0001209191-21-023909 · doc4.xml · nonDerivative · entry 4 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,367,157 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.07 to $31.40 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 01:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 19,207 | $30.82 | $591,959.74 |
DisclosureSEC source: 0001209191-21-023909 · doc4.xml · nonDerivative · entry 3 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,370,433 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.07 to $31.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 29, 2021 Filed Apr 1, 2021 01:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 764 | $33.16 | $25,334.24 |
DisclosureSEC source: 0001209191-21-023909 · doc4.xml · nonDerivative · entry 2 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,389,640 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.04 to $33.62 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 29, 2021 Filed Apr 1, 2021 01:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 1,410 | $31.60 | $44,556.00 |
DisclosureSEC source: 0001209191-21-023909 · doc4.xml · nonDerivative · entry 1 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,390,404 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.32 to $32.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 26, 2021 Filed Mar 26, 2021 22:20 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 35,268 | $33.44 | $1,179,361.92 |
DisclosureSEC source: 0001209191-21-023299 · doc4.xml · nonDerivative · entry 8 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,391,814 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.85 to $33.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 22:20 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 1,200 | $34.82 | $41,784.00 |
DisclosureSEC source: 0001209191-21-023299 · doc4.xml · nonDerivative · entry 7 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,427,082 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.64 to $35.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 22:20 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 3,787 | $34.17 | $129,401.79 |
DisclosureSEC source: 0001209191-21-023299 · doc4.xml · nonDerivative · entry 6 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,428,282 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.58 to $34.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 22:20 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 61,340 | $32.94 | $2,020,539.60 |
DisclosureSEC source: 0001209191-21-023299 · doc4.xml · nonDerivative · entry 5 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,432,069 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $33.46 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 22:20 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 10,100 | $39.00 | $393,900.00 |
DisclosureSEC source: 0001209191-21-023299 · doc4.xml · nonDerivative · entry 4 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,493,409 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.50 to $39.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 22:20 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 700 | $37.51 | $26,257.00 |
DisclosureSEC source: 0001209191-21-023299 · doc4.xml · nonDerivative · entry 3 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,503,509 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.11 to $37.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 22:20 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 5,079 | $36.53 | $185,535.87 |
DisclosureSEC source: 0001209191-21-023299 · doc4.xml · nonDerivative · entry 2 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,504,209 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.06 to $37.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 22:20 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | SaleCommon Stock | 19,002 | $35.12 | $667,350.24 |
DisclosureSEC source: 0001209191-21-023299 · doc4.xml · nonDerivative · entry 1 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,509,288 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.51 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 08, 2021 Filed Mar 5, 2022 00:22 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | PurchaseCommon Stock | 300,000 | $45.00 | $13,500,000.00 |
DisclosureSEC source: 0001209191-22-016484 · doc4.xml · nonDerivative · entry 4 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Nextech VI Oncology SCSp Disclosed balance after: 300,000 F3 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:48 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | ConversionSeries C Preferred Stock · Derivative | 1,578,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-062394 · doc4.xml · derivative · entry 5 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Nextech VI Oncology SCSp Disclosed balance after: 0 Underlying: Common Stock · 425,063 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F3 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F3 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:48 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | ConversionSeries B Preferred Stock · Derivative | 4,629,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-062394 · doc4.xml · derivative · entry 4 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Nextech VI Oncology SCSp Disclosed balance after: 0 Underlying: Common Stock · 1,246,870 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F3 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F3 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:48 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | ConversionCommon Stock | 425,063 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-062394 · doc4.xml · nonDerivative · entry 3 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Nextech VI Oncology SCSp Disclosed balance after: 1,910,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F3 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:48 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | ConversionCommon Stock | 1,246,870 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-062394 · doc4.xml · nonDerivative · entry 2 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Nextech VI Oncology SCSp Disclosed balance after: 1,484,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F3 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:48 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | PurchaseCommon Stock | 238,096 | $21.00 | $5,000,016.00 |
DisclosureSEC source: 0001209191-20-062394 · doc4.xml · nonDerivative · entry 1 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Nextech VI Oncology SCSp Disclosed balance after: 238,096 F1 · kind: The shares were purchased in the Issuer's initial public offering. F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 20:37 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries D Preferred Stock · Derivative | 760,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052336 · doc4.xml · derivative · entry 4 Schroeder Thilo · CIK 0001776412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 760,267 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 20:37 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionSeries C Preferred Stock · Derivative | 1,768,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052336 · doc4.xml · derivative · entry 3 Schroeder Thilo · CIK 0001776412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,768,023 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 20:37 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 760,267 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052336 · doc4.xml · nonDerivative · entry 2 Schroeder Thilo · CIK 0001776412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,528,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 20:37 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | ConversionCommon Stock | 1,768,023 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052336 · doc4.xml · nonDerivative · entry 1 Schroeder Thilo · CIK 0001776412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,768,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 13, 2020 Filed Mar 5, 2022 00:22 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | PurchaseCommon Stock | 150,000 | $26.00 | $3,900,000.00 |
DisclosureSEC source: 0001209191-22-016484 · doc4.xml · nonDerivative · entry 3 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Nextech V Oncology S.C.S., SICAV-SIF Disclosed balance after: 2,668,214 F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| February 18, 2020 Filed Mar 5, 2022 00:22 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | ConversionSeries C Preferred Stock · Derivative | 548,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016484 · doc4.xml · derivative · entry 10 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Nextech V Oncology S.C.S., SICAV-SIF Disclosed balance after: 0 Underlying: Common Stock · 548,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| February 18, 2020 Filed Mar 5, 2022 00:22 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | ConversionSeries B Preferred Stock · Derivative | 1,569,539 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016484 · doc4.xml · derivative · entry 9 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Nextech V Oncology S.C.S., SICAV-SIF Disclosed balance after: 0 Underlying: Common Stock · 1,569,539 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| February 18, 2020 Filed Mar 5, 2022 00:22 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | PurchaseCommon Stock | 400,000 | $17.00 | $6,800,000.00 |
DisclosureSEC source: 0001209191-22-016484 · doc4.xml · nonDerivative · entry 2 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Nextech V Oncology S.C.S., SICAV-SIF Disclosed balance after: 2,518,214 F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| February 18, 2020 Filed Mar 5, 2022 00:22 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | ConversionCommon Stock | 2,118,214 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016484 · doc4.xml · nonDerivative · entry 1 Schroeder Thilo · CIK 0001776412 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Nextech V Oncology S.C.S., SICAV-SIF Disclosed balance after: 2,118,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.